Education
About Us
Working with TipRanks
Follow Us
Vaxart (VXRT)
OTHER OTC:VXRT
Earnings Data
Report Date
May 19, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.02Last Year’s EPS
-0.07Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed several strong positives: a significant strategic partnership with Dynavax (now Sanofi) with meaningful upfront consideration and large potential upside, a substantial year-over-year revenue increase driven by government contracts and the licensing transaction, robust and published norovirus clinical data demonstrating safety and durable mucosal IgA responses (including exploratory infant passive transfer), and active cost management that extends runway into 2027. Offsetting these positives are meaningful execution risks and timing uncertainties: a BARDA stop-work reduced planned Phase 2b enrollment (from 10,000 planned to ~5,400 enrolled), immunogenicity readouts are delayed and contingent on BARDA, the norovirus next study requires partner funding, and the strong 2025 revenue was largely contract-driven rather than recurring commercial revenue. On balance, the highlights—large partnership validation, major revenue pickup, and encouraging clinical data—outweigh the operational and timing challenges, supporting a constructive outlook but with clear dependency on partners and future data readouts.Company Guidance
Strategic Partnership with Dynavax (now Sanofi)
Entered a license and collaboration agreement (Nov 2025) with Dynavax, receiving $25,000,000 upfront and a $5,000,000 equity investment; potential additional $50,000,000 upon Dynavax electing to continue development after Phase 2b FDA submission; total potential deal value up to $700,000,000 including up to $195,000,000 in regulatory milestones, $425,000,000 in sales milestones, and tiered royalties in the low- to mid-teens.
Large Year-over-Year Revenue Increase
Reported full year 2025 revenue of $237.3 million versus $28.7 million in 2024, an increase of approximately 727% year-over-year, driven primarily by BARDA government contracts and revenue recognized from the Dynavax license and collaboration agreement.
Published Positive Norovirus Clinical Data
Published full dataset from Phase 1 dose-ranging study in lactating mothers (n=76) in NPJ Vaccines (Jan 2026). Vaccine was safe and well tolerated; serum norovirus-specific IgA rose ~5.6-fold (G11) and ~4.7-fold (G24) in the high-dose group; breast milk IgA rose ~4-fold (G11) and ~6-fold (G24) at day 29 and was maintained through day 180; exploratory evidence suggests passive transfer of IgA to infants (infant stool increases at days 29 and 60).
Second-Generation Constructs Show Strong Immunogenicity Gains
Head-to-head Phase 1 results (reported June 2025) showed second-generation norovirus constructs produced significantly higher antibody responses versus first-generation: a 141% increase for one strain and a 94% increase for the other—supporting platform improvements applied across COVID-19, flu, and HPV programs.
Cash Position and Extended Runway
Ended Q4 2025 with $63.8 million in cash, cash equivalents, and investments and guidance indicating cash runway into 2027; management is pursuing strategic partnerships and non-dilutive funding to extend runway further.
Operational Cost Management
Entered a lease termination agreement to end a lease early (from 03/31/2029 to 05/15/2026), expected to provide significant operating cost savings and better focus of financial resources on lead programs.
VXRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VXRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 12, 2026 | $0.74 | $0.63 | -14.38% |
Nov 13, 2025 | $0.36 | $0.41 | +10.96% |
Aug 13, 2025 | $0.37 | $0.36 | -2.44% |
May 13, 2025 | $0.41 | $0.40 | -3.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vaxart (VXRT) report earnings?
Vaxart (VXRT) is schdueled to report earning on May 19, 2026, TBA (Confirmed).
What is Vaxart (VXRT) earnings time?
Vaxart (VXRT) earnings time is at May 19, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VXRT EPS forecast?
VXRT EPS forecast for the fiscal quarter 2026 (Q1) is 0.02.